A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

Among his first actions as president, Donald Trump has rescinded an executive order signed during the Biden administration ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

Inflammatix has secured the FDA’s blessing for its in vitro diagnostic system, aimed at rapidly profiling the body’s response ...

Clinical research tech firm Advarra has unveiled a new digital solution meant to help speed up study starts and facilitate ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Disc Medicine has finalized the design of the confirmatory trial for its rare blood disorder drug candidate, adding a ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Many of the most devastating infectious diseases are caused by RNA viruses, and Model Medicines is working on one compound to ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...